Scalable Treg Therapy for Transplants & Autoimmune Disorder
Regulatory T Cell Therapy for Immune-related Diseases
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This HKU innovation presents a scalable and cost-effective method to generate allogeneic-specific CD4+ and CD8+ regulatory T cells (Tregs) from naïve precursors, addressing limitations in traditional immunosuppressive therapies. The technology enables targeted immune tolerance in transplantation-related diseases, autoimmune conditions, and allergies without requiring donor-recipient HLA matching. Applications include therapies to prevent graft rejection, treat autoimmune diseases, and manage allergies. The method avoids global immune suppression, reducing severe side effects like infections and tumor relapse. Protected by patents in the US, China, and Europe, this breakthrough advances personalized and efficient immunotherapy solutions.
IP Type or Form Factor: Patent Granted; Process & Method; Material
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Biotechnology; Healthcare Provider
